
|Articles|September 13, 2017
Should the Availability of High-Dose Opioids Be Reduced?
In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.
Advertisement
In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Etuvetidigene Autotemcel, First Gene Therapy for Wiskott-Aldrich Syndrome
2
How Next-Generation CDK Inhibitors Are Redefining Post–CDK4/6 Therapy in HR+/HER2– Metastatic Breast Cancer
3
FDA Approves First At-Home Treatment Device for Depression
4
Automation and Standardization Take Center Stage in Health System’s Centralized IV Compounding Strategy
5


















































































































































































































